Embecta Corp.

Embecta Corp. announced it will host a conference call on Friday, August 7, 2026, at 8:00 a.m. ET to discuss its fiscal third quarter 2026 financial results. The call will also provide an operational update and include a question and answer session. Investors can access the live webcast or teleconference, with a replay available on the company's investor relations website.

Embecta Corp. announced the appointment of Nimish Muzumdar as Senior Vice President and President, North America, effective June 15, 2026. Mr. Muzumdar will be responsible for leading the company's commercial teams in the U.S. and Canada and driving the region's long-term growth strategy. He brings extensive experience from Sandoz, where he led a $1 billion generics division to profitable growth. As an inducement for his employment, Mr. Muzumdar received a long-term incentive award of 638,978 time-vested restricted stock units.

Embecta Corp. announced that its management will participate in four investor events throughout June 2026. These events include the Jefferies Global Healthcare Conference, TD Cowen Diabetes Tech Summit, Goldman Sachs 47th Annual Global Healthcare Conference, and Truist Securities MedTech Conference. Management will engage with investors through one-on-one meetings and a fireside session.

Embecta Corp. announced the completion of its previously announced acquisition of Owen Mumford Holdings Limited, a UK-based innovator and manufacturer of medical devices and drug-delivery technologies. The transaction involved an upfront cash payment of 100 million, with potential additional payments of up to 50 million based on the achievement of commercial milestones related to Aidaptus auto-injector sales. This acquisition is expected to accelerate Embecta's strategic transformation, providing a differentiated drug-delivery platform and expanding its chronic care device portfolio.

Embecta Corp. announced a definitive agreement to acquire Owen Mumford Holdings Limited for approximately £150 million, comprising an upfront cash payment of £100 million and up to £50 million in commercial milestone payments. The transaction is expected to close in Q3 fiscal year 2026. For the second quarter ended March 31, 2026, Embecta reported a net loss of $(4.1) million on revenues of $221.8 million, a significant decline from the prior year. However, for the six-month period, net income increased to $40.0 million, and long-term debt was reduced.

Embecta Corp. reported disappointing second quarter fiscal year 2026 financial results, with revenues down 14.4% to $221.8 million and a net loss of $(4.1) million. The company significantly lowered its full-year 2026 financial guidance, citing increased competitive dynamics and softness in U.S. market volumes. In response, Embecta initiated a review of its cost structure, authorized a three-year $100 million share repurchase program, and reduced its quarterly dividend from $0.15 to $0.01 per share. The acquisition of Owen Mumford is still on track to close in May 2026.

Embecta Corp. announced it reported its second quarter fiscal 2026 financial results. The company will host a conference call and live audio webcast for analysts and investors today, May 5, 2026, at 8:00 a.m. ET. The detailed earnings press release and investor presentation are available on Embecta's Investor Relations website. A webcast replay of the call will be accessible from 11:00 a.m. ET and archived for one year.

Embecta Corp.'s Board of Directors has declared a quarterly cash dividend of $0.01 per share. This dividend is scheduled to be paid on June 15, 2026, to shareholders who are on record as of the close of business on May 28, 2026. The company continues its legacy in insulin delivery, aiming to become a broad-based medical supplies company.

Embecta Corp. announced it will host a conference call on Tuesday, May 5, 2026, at 8:00 a.m. Eastern Time. The call will cover the company's fiscal second quarter 2026 financial results and provide an operational update, followed by a Q&A session. Investors can access the live webcast or teleconference, with a replay available on the company's investor relations website from 11:00 a.m. ET on the same day.